Compare Novavax Inc (NVAX) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Novavax Inc trades at $8.12 (market cap $1.30B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.9. The key difference: Novavax Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| NVAX | SJNK | |
|---|---|---|
Market Cap | $1.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $11.19 | $25.63 |
52-Week Low | $6.22 | $24.75 |
Enterprise Value | $800.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
SJNK trades at $24.92 with no change over the past 24 hours, reflecting stability amid a bearish technical signal from moving averages. The ETF maintains a neutral stance in oscillators, with RSI levels indicating neither overbought nor oversold conditions. Recent corporate actions include scheduled dividend payments, with H2-26 set at $0.15 per share. Institutional activity shows Balefire LLC reduced its stake by 74.7% in the latest quarter, as per SEC filings dated 2026-07-21.
The outlook for SJNK is cautious due to bearish technical indicators and negative sentiment from analysts, who rate it SELL citing exhausted tailwinds from falling yields. Risks include high sensitivity to interest rate changes and credit spread volatility. Investment opportunity lies in its high-yield bond focus, but current conditions suggest limited near-term upside amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
